Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in CHB Patients.

In their recent report, Goh et al. divided hepatitis B virus (HBV) infected patients into statin users (≥28 cDDD [cumulative defined daily dose]) and non-users. They concluded that statins users have a lower risk of developing hepatocellular carcinoma (HCC) than statin non-users.(1) However, several limitations may temper its conclusions.